Screener
Fulgent Genetics, Inc. FLGT Q2 2026 earnings
Reported July 30, 2026 · After market close
Revenue$85.4MMiss by $8.6M
EPS-$0.58Miss by $0.12
Revenue estimate$94.0M
EPS estimate-$0.46
“In the second quarter, we had the honor of presenting the encouraging findings from Phase 2 data for FID-007 at the 2026 American Society of Clinical Oncology (ASCO) meeting, and we are encouraged by our clinical trial progress for both FID-007 and FID-022. We continue to execute on our strategic initiatives in our laboratory services business as we expand our AI portfolio and integrate digital pathology and are seeing a real impact from our AI tools with improved efficiency and quality.”
Next report
Nov 6, 2026 (in 2 months)Revenue estimate$86.3M
EPS estimate-$0.65
Valuation & ratios
Valuation
as of 09/17/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Fulgent Genetics, Inc. report Q2 2026 earnings?
- Fulgent Genetics, Inc. (FLGT) reported Q2 2026 earnings on July 30, 2026 after market close.
- What were Fulgent Genetics, Inc.'s Q2 2026 revenue and EPS?
- Fulgent Genetics, Inc. reported revenue of $85.4M and eps of $-0.58 for Q2 2026.
- Did Fulgent Genetics, Inc. beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $94.0M by $8.6M. EPS missed the consensus estimate of $-0.46 by $0.12.
- How did Fulgent Genetics, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 4.4% from $81.8M a year earlier.
- Where can I find Fulgent Genetics, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-326119) and the 10-Q periodic report (0001193125-26-326136) directly on SEC EDGAR. The filing index links above go to sec.gov.
